A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma

Trial Profile

A Randomized Phase II Study of Multipeptide Vaccination With or Without IL-12, Then Combined With Regulatory T Cell Depletion Using Daclizumab in Patients With Metastatic Melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2016

At a glance

  • Drugs Daclizumab (Primary) ; Interleukin-12 (Primary) ; MelanA gp100 MAGE3 NA174 peptide vaccine (Primary) ; Montanide ISA-51; Subunit vaccines; Subunit vaccines
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Aug 2016 Status changed from active, no longer recruiting to discontinued.
    • 15 Aug 2012 Planned End Date 1 Dec 2013 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top